How political red tape and a drug company’s thirst for profits limited the reach of a drug that experts believe could have reduced the opioid epidemic’s toll.
How political red tape and a drug company’s thirst for profits limited the reach of a drug that experts believe could have reduced the opioid epidemic’s toll.
Credit...Photo illustration by Ben Denzer
Supported by
By Shoshana Walter
Shoshana Walter has reported on addiction and the impact of drug laws for almost 10 years. She interviewed dozens of sales reps, executives, doctors, patients, researchers, investigators and federal officials for this article.
Buprenorphine, one of the most effective medications for treating opioid addiction is still hard to find at U.S. pharmacies,…
Patients of PHA Healthcare, a treatment program in Baltimore, were housed in drug-ridden buildings where many overdosed, an…
STAT examines America's failure to address excessive alcohol use across decades.
Over-the-counter sales for the overdose reversal drug naloxone have been low, a trend researchers reported is likely due to its…
Trump’s budget law effectively undoes much of the good that the Affordable Care Act did in reducing opioid deaths.
More than 5,000 shelved drug candidates were discontinued for business reasons, not safety ones. A new push aims to match them…
